PRINCETON, NJ, USA I SHANGHAI and SUZHOU, China I December 3, 2024 I Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the ...
BOSTON, MA, USA I 03, 2024 I AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic ...
Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed ...
BASEL, Switzerland and LONDON, UK and NEW YORK, NY, USA I 03, 2024 I Kinevant Sciences, a clinical-stage biopharmaceutical company developing new ...
TORINO, Italy I 03, 2024 I Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding ...
In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body ...
Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback